#ACR21 L19: TitAIN: Secukinumab for GCA ⭐️Phase 2 study with n=52 ⭐️70% of SEC sustained remission at wk 28 vs 20% PBO, 59% at week 52 vs 8% ⬇️Cumulative prednisolone through wk 52 (2.8g v 3.4g) - Looking forward to larger study @Rheumnow https://t.co/cuM9LcEr4u https://t.co/TmyS0kixFg

• https://bit.ly/3mUsMUp

IL-17i for GCA? TitAIN study met all endpoints! phase II: 52 pt DBRPCT 1:1 for 52 weeks secukinumab vs PCB 👉effective sustained remission 👉longer time to GCA flare 👉lower dose of steroids by week 52 👉no increase in AEs #ACR21 @rheumnow Abst#L19 https://t.co/Xi3Iz6Em0R

Secukinumab in GCA, phase 2 (TitAIN): I can't deny this is promising, but phase 2 needs to be interesting both arms did worse than equivalents in GiACTA, TCZ phase 2 (?looser flare def) @drpnash: "Bring on the phase 3 trials" (recruitment started👀) #ACR21 ABSTL19 @RheumNow https://t.co/25OAL9BqIZ

ARIAA Study - Abatacept Reverses ACPA+ Subclinical Arthritis: Dr. Jack Cush discusses abstract #0455, a preclinical RA intervention trial - abatacept or placebo given to at risk individuals (arthralgias, CCP+, MRI+) for 6 months, presented at #ACR21. https://t.co/fz1hPTleMn https://t.co/V4PsPZ0ZwF

• https://bit.ly/3o2XwC2

Impressive case of vasculitis – should be part of @ACRheum image bank #ThievesMarket #ACR21 Abst#TM20 @rheumnow https://t.co/YiBikROuzb

Dr. Despotovic shares general principles about ICU admissions in patients w/ #rheumatic disease. 🔺#SLE, RA, systemic #vasculitis, SSc, IIMs 🔺serologic testing useful but interpret w/n clinical context @RheumNow #ACR21 https://t.co/jb3Mt31dZz

What is the effect of #avacopan on renal function in pts with #ANCA #vasculitis? 👉🏼Results from ADVOCATE show greater recovery of kidney function with avacopan vs steroids 👉🏼Particularly marked in pts with CKD4 and eGFR<60 Abs#L14 #ACR21 @RheumNow https://t.co/5z7YulxVAj https://t.co/LnJr4gLuTV

• Effect of Avacopan, a Selective C5a Receptor Inhibitor, on Kidney Function in P…

Avacopan effects on renal disease in AAV presented in further detail. Greater recovery with avacopan, which was accentuated in those with worse renal disease or proteinuria at baseline. Abstr#L14 #ACR21 @RheumNow https://t.co/dfTmhhsNnX

Avacopan (C5a inhibitor) is a new promising therapy for ANCA vasculitis. US FDA approved in Oct 2021 #ACR21 @rheumnow https://t.co/tWvKzHOT5V

Dr Doliner @zach_wallace_md on ILD in AAV. ILD in 13% - of which 76% fibrotic. UIP most common. Most MPO+, but also rarely seen with PR3+. 47% ⬆️ risk of death. Abstr#0430 #ACR21 @RheumNow https://t.co/6MnxqW92bz

Dr O'Brien on co-existent AAV and RA. Not something I'm used to seeing, but maybe we need to think about it more? 25 cases with RA+AAV, 52 with RA + ANCA but no AAV, not sure what the denominator is here though. Abstr#0428 #ACR21 @RheumNow @profgayecunnane https://t.co/fN3BRpc7UJ

Dr. D.McGonagle on the patterns of dse ➡true #vasculitis vs. vasculitis mimics seen in skin of #COVID19 pts in this very informative slide 🔴Mild/no lung dse: vasc cuffing,⬆type1 IFN 🔴Severe dse: vasc occlusion,⬇type1 IFN @RheumNow #ACR21 #MedTwitter https://t.co/Y5S2k7LO1p https://t.co/puBJm4Kd8H

• DEFINE_ME

DCVAS testing results in GCA. @davidliew @philipcrobinson are you guys essentially not imaging anyone in anyway? What's going on? #ACR21 @RheumNow https://t.co/IMr5ee2Iea